Edgewise Therapeutics, Inc.(EWTX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Edgewise Therapeutics, Inc. (EWTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. EWTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Edgewise Therapeutics, Inc. reports net income of $-57.3M, free cash flow of $-42.5M. Top institutional holders of EWTX by reported 13-F value include ORBIMED ADVISORS, Paradigm Biocapital Advisors, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. EWTX trades on the Nasdaq exchange and files with the SEC under CIK 1710072. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EWTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edgewise Therapeutics, Inc. directly from SEC EDGAR.